1
|
Raja R, Wu C, Bassoy EY, Rubino T, Utagawa E, Magtibay P, Butler K, Curtis M. Abstract 4455: Protein phosphatase 4 inhibition stimulates anti-tumor immunity in ovarian cancer. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-4455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Background: Increased infiltration of T cells into ovarian tumors has been repeatedly shown to be predictive of enhanced patient survival. However, despite the evidence of an active immune response in OC, immune checkpoint blockade therapy has been ineffective. Recently studies have shown that deficiencies in the DNA damage response (DDR) can drive increased genomic instability and tumor immunogenicity. One target involved in the DDR that has the potential to be of therapeutic value is protein phosphatase 4 (PP4); however, the effect of PP4 deficiency on anti-tumor immunity remain unknown.
Results: Our results show that PP4 inhibition combined with carboplatin leads to increased carboplatin sensitivity, DNA damage, and micronuclei formation. Using a panel of ovarian cancer cells, we show that PP4 inhibition triggers inflammatory signaling via NF-κB and STAT1 activation resulting in increased expression of pro-inflammatory cytokines including IFNβ1, CCL5, CXCL10, and IL-6. Moreover, conditioned media from OC cells treated with the combination of PP4 inhibitor and carboplatin significantly increased migration of both CD8 T cell and NK cells over carboplatin treatment alone. Knockdown of STING in OC cells significantly abrogated the increase in CD8 T cell migration induced by PP4 inhibition. PPP4C or PPP4R3B knockdown resulted in strong induction of NK cell IFN-γ, increased degranulation, and increased NK cell-mediated cytotoxicity against OC cells. Stable knockdown of PP4C in a syngeneic, immunocompetent mouse model of ovarian cancer resulted in significant reduction of tumor growth in vivo. PP4C low tumors had increased infiltration of CD161+ NK cells and CD4+ T cells. Addition of low dose carboplatin treatment in vivo led to increased CD8+ T cell infiltration in PP4C low tumors when compared to the untreated groups.
Conclusions: Our work has identified a role for PP4 inhibition in promoting anti-tumor immune activation. These findings provide the rationale for combining PP4 inhibitors with immunotherapy as a new approach in ovarian cancer treatment.
Citation Format: Remya Raja, Christopher Wu, Esen Y. Bassoy, Thomas Rubino, Emma Utagawa, Paul Magtibay, Kristina Butler, Marion Curtis. Protein phosphatase 4 inhibition stimulates anti-tumor immunity in ovarian cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4455.
Collapse
|
2
|
Goldstein JD, Bassoy EY, Caruso A, Palomo J, Rodriguez E, Lemeille S, Gabay C. IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis. Life Sci Alliance 2020; 3:e202000688. [PMID: 32345660 PMCID: PMC7190273 DOI: 10.26508/lsa.202000688] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Revised: 04/15/2020] [Accepted: 04/16/2020] [Indexed: 01/04/2023] Open
Abstract
IL-36R signaling plays an important role in the pathogenesis of psoriasis. We ought to assess the specific function of IL-36R in keratinocytes for the pathology of Aldara-induced psoriasis-like dermatitis. Il36r ΔK mice presenting deletion of IL-36R in keratinocytes were similarly resistant to Aldara-induced ear inflammation as Il36r -/- mice, but acanthosis was only prevented in Il36r -/- mice. FACS analysis revealed that IL-36R signaling in keratinocytes is mandatory for early neutrophil infiltration in Aldara-treated ears. RNASeq and qRT-PCR experiments demonstrated the crucial role of IL-36R signaling in keratinocytes for induction of IL-23, IL-17, and IL-22 at early time points. Taken together, our results demonstrate that IL-36R signaling in keratinocytes plays a major role in the induction of Aldara-induced psoriasis-like dermatitis by triggering early production of IL-23/IL-17/IL-22 cytokines and neutrophil infiltration.
Collapse
Affiliation(s)
- Jérémie D Goldstein
- Department of Pathology-Immunology, University of Geneva Faculty of Medicine, Geneva, Switzerland
| | - Esen Y Bassoy
- Department of Pathology-Immunology, University of Geneva Faculty of Medicine, Geneva, Switzerland
| | - Assunta Caruso
- Department of Pathology-Immunology, University of Geneva Faculty of Medicine, Geneva, Switzerland
| | - Jennifer Palomo
- Department of Pathology-Immunology, University of Geneva Faculty of Medicine, Geneva, Switzerland
| | - Emiliana Rodriguez
- Department of Pathology-Immunology, University of Geneva Faculty of Medicine, Geneva, Switzerland
| | - Sylvain Lemeille
- Department of Pathology-Immunology, University of Geneva Faculty of Medicine, Geneva, Switzerland
| | - Cem Gabay
- Department of Pathology-Immunology, University of Geneva Faculty of Medicine, Geneva, Switzerland
- Division of Rheumatology, Department of Medicine, University Hospitals of Geneva, Geneva, Switzerland
| |
Collapse
|
3
|
Nunes-Hasler P, Maschalidi S, Lippens C, Castelbou C, Bouvet S, Guido D, Bermont F, Bassoy EY, Page N, Merkler D, Hugues S, Martinvalet D, Manoury B, Demaurex N. STIM1 promotes migration, phagosomal maturation and antigen cross-presentation in dendritic cells. Nat Commun 2017; 8:1852. [PMID: 29176619 PMCID: PMC5701258 DOI: 10.1038/s41467-017-01600-6] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2016] [Accepted: 10/02/2017] [Indexed: 12/31/2022] Open
Abstract
Antigen cross-presentation by dendritic cells (DC) stimulates cytotoxic T cell activation to promote immunity to intracellular pathogens, viruses and cancer. Phagocytosed antigens generate potent T cell responses, but the signalling and trafficking pathways regulating their cross-presentation are unclear. Here, we show that ablation of the store-operated-Ca2+-entry regulator STIM1 in mouse myeloid cells impairs cross-presentation and DC migration in vivo and in vitro. Stim1 ablation reduces Ca2+ signals, cross-presentation, and chemotaxis in mouse bone-marrow-derived DCs without altering cell differentiation, maturation or phagocytic capacity. Phagosomal pH homoeostasis and ROS production are unaffected by STIM1 deficiency, but phagosomal proteolysis and leucyl aminopeptidase activity, IRAP recruitment, as well as fusion of phagosomes with endosomes and lysosomes are all impaired. These data suggest that STIM1-dependent Ca2+ signalling promotes the delivery of endolysosomal enzymes to phagosomes to enable efficient cross-presentation. STIM proteins sense Ca2+ depletion in the ER and activate store-operated Ca2+-entry (SOCE) in response, a process associated with dendritic cell functions. Here the authors show STIM1 is the major isoform controlling SOCE in mouse dendritic cells and provide a mechanism for its requirement in antigen cross-presentation.
Collapse
Affiliation(s)
- Paula Nunes-Hasler
- Department of Cell Physiology and Metabolism, University of Geneva, Geneva, 1211, Switzerland.
| | - Sophia Maschalidi
- Laboratory of Normal and Pathological Homeostasis of the Immune System, INSERM UMR1163, Paris, 75015, France.,Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine Paris Descartes, Paris, 75015, France
| | - Carla Lippens
- Department of Pathology and Immunology, University of Geneva, Geneva, 1211, Switzerland
| | - Cyril Castelbou
- Department of Cell Physiology and Metabolism, University of Geneva, Geneva, 1211, Switzerland
| | - Samuel Bouvet
- Department of Cell Physiology and Metabolism, University of Geneva, Geneva, 1211, Switzerland
| | - Daniele Guido
- Department of Cell Physiology and Metabolism, University of Geneva, Geneva, 1211, Switzerland
| | - Flavien Bermont
- Department of Cell Physiology and Metabolism, University of Geneva, Geneva, 1211, Switzerland
| | - Esen Y Bassoy
- Department of Cell Physiology and Metabolism, University of Geneva, Geneva, 1211, Switzerland
| | - Nicolas Page
- Department of Pathology and Immunology, University of Geneva, Geneva, 1211, Switzerland
| | - Doron Merkler
- Department of Pathology and Immunology, University of Geneva, Geneva, 1211, Switzerland.,Division of Clinical Pathology, Geneva University Hospital, Geneva, 1211, Switzerland
| | - Stéphanie Hugues
- Department of Pathology and Immunology, University of Geneva, Geneva, 1211, Switzerland
| | - Denis Martinvalet
- Department of Cell Physiology and Metabolism, University of Geneva, Geneva, 1211, Switzerland
| | - Bénédicte Manoury
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine Paris Descartes, Paris, 75015, France.,Institut National de la Santé et de la Recherche Médicale, Unité 1151, Paris, 75014, France.,Centre National de la Recherche Scientifique, Unité 8253, Paris, 75014, France
| | - Nicolas Demaurex
- Department of Cell Physiology and Metabolism, University of Geneva, Geneva, 1211, Switzerland
| |
Collapse
|